Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment
01:50pm, Tuesday, 02'nd Jul 2024
The approval Tuesday of Eli Lilly's LLY -0.53%decrease; red down pointing triangle new Alzheimer's drug will hasten the transformation of treatment of the dementia-causing condition.
Weighing the Future of Weight Loss Drugs
01:44pm, Tuesday, 02'nd Jul 2024
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
01:35pm, Tuesday, 02'nd Jul 2024
Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of d
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
11:38am, Tuesday, 02'nd Jul 2024
The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices th
LLY & NVDA: Some of the Best Trends of All Time
10:44am, Tuesday, 02'nd Jul 2024
Eli Lilly (LLY) and Nvidia (NVDA) are seeing some of the best trends of all time, notes Jerry Parker. He discusses trends to watch in the second half of the year.
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
10:06am, Tuesday, 02'nd Jul 2024
Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.
5 Top-Performing S&P 500 Stocks of 1H Set to Shine Further
05:16am, Tuesday, 02'nd Jul 2024
The S&P 500 wraps up the first half with gains of 14%, representing one of the strongest performances since the late-1990s dot-com bubble.
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
10:39am, Monday, 01'st Jul 2024
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used o
Eli Lilly Soars To 52-Week High: Can The Momentum Continue?
09:27am, Monday, 01'st Jul 2024
Eli Lilly and Company LLY has hit a new 52-week high, climbing to $915.54 during Friday trading. The stock is up a remarkable 97.38% over the past year and 55.32% year-to-date, fueled by groundbreakin
India panel urges drug regulator to approve Lilly's obesity drug Mounjaro
08:33am, Monday, 01'st Jul 2024
An Indian government-approved expert panel has advised the country's drug regulator to approve the import and sale of U.S. drugmaker Eli Lilly's Mounjaro, a blockbuster diabetes drug and a wildly popu
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
07:37am, Monday, 01'st Jul 2024
Secured by a $159 billion order backlog, Lockheed Martin's dividend payments are as dependable as they get. Eli Lilly can help you cash in on the booming $130 billion weight-loss drug market.
Top Growth And Dividend Long-Term Stocks For Mid-Year 2024
09:00pm, Sunday, 30'th Jun 2024
The Top Dividend Growth stock model aims to deliver optimal total return with reliable growth factors and high dividends for higher profitability long-term. Only one stock of the 15 largest Mega Cap s
5 Reasons Eli Lilly Just Keeps Rising
11:21am, Sunday, 30'th Jun 2024
Despite high market multiples, the Eli Lilly stock has outperformed the S&P 500 Health Care Index YTD, and this might just continue. Strong Q1 2024 performance leading to an upgraded guidance for the
2 Top Healthcare Stocks to Buy in June
07:52am, Sunday, 30'th Jun 2024
These profitable businesses are leaders in their respective healthcare sectors. Intuitive Surgical is the global market leader in surgical robotics, with a sneaky recurring revenue model.
This Is Massive News for Eli Lilly Investors
07:00am, Saturday, 29'th Jun 2024
Eli Lilly has been working on a drug called donanemab to treat Alzheimer's disease. This market is estimated to reach more than $30 billion by the next decade.
